Effect of Sacubitril/valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: a Real World Study

Capital Medical University

Status: Enrolling

Conditions: Hypertension; Obesity; Sacubitril/valsartan

Treatments: Drug: Sacubitril / Valsartan Oral Tablet [Entresto]; Drug: ACEI/ARB

Study type: Observational

Funder types: Other

Identifiers

NCT05498675

2022-P2-173-01

Details and patient eligibility

About

The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.

Full description

Obesity is one of the risk factors of hypertension, and affects cardiac structure and function in the long term for hypertensive patients. Sacubitril/valsartan is regarded as a better antihypertensive drug for the improvement of cardiac function for patients with heart failure, but it remains unclear whether there are differences among different BMI groups. Therefore, the aim of this study was to evaluate the benefit of sacubitril/valsartan versus other antihypertensive drugs on cardiac structure and function assessed by CMR in hypertensive patients stratified by BMI in the real world.

Enrollment: 180 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with essential hypertension
• 18-70 years old
• No major barriers to provide written consent

Exclusion criteria

• Secondary hypertension, except because of sleep apnea
• cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months
• Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)
• Unable to understand or comply with the study procedures

Trial design

180 participants in 2 patient groups

Sacubitril/valsartan group

Description:

Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.

Treatment:

Drug: Sacubitril / Valsartan Oral Tablet [Entresto]

ACEI/ARB group

Description:

Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group. Including: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.

Treatment:

Drug: ACEI/ARB